PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Brii Biosciences Ltd (2137.HK)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISINKYG1645A1094
SectorHealthcare
IndustryBiotechnology

Highlights

Market CapHK$757.98M
Revenue (TTM)HK$55.89M
Gross Profit (TTM)HK$147.19M
EBITDA (TTM)-HK$536.79M
Year RangeHK$0.85 - HK$4.56
Target PriceHK$4.77

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Brii Biosciences Ltd

Performance

Performance Chart

The chart shows the growth of an initial investment of HK$10,000 in Brii Biosciences Ltd, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-60.00%-40.00%-20.00%0.00%20.00%40.00%NovemberDecember2024FebruaryMarchApril
-55.51%
18.99%
2137.HK (Brii Biosciences Ltd)
Benchmark (^GSPC)

S&P 500

Returns By Period

Brii Biosciences Ltd had a return of -55.70% year-to-date (YTD) and -76.62% in the last 12 months.


PeriodReturnBenchmark
Year-To-Date-55.70%5.05%
1 month6.32%-4.27%
6 months-55.51%18.82%
1 year-76.62%21.22%
5 years (annualized)N/A11.38%
10 years (annualized)N/A10.42%

Monthly Returns Heatmap


JanFebMarAprMayJunJulAugSepOctNovDec
2024-28.95%2.47%-45.18%
2023-11.93%-3.98%15.77%-18.28%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of 2137.HK is 4, indicating that it is in the bottom 4% of the market in terms of risk-adjusted performance. This ranking is based on the combined values of the indicators listed below.

The Risk-Adjusted Performance Rank of 2137.HK is 44
Brii Biosciences Ltd(2137.HK)
The Sharpe Ratio Rank of 2137.HK is 33Sharpe Ratio Rank
The Sortino Ratio Rank of 2137.HK is 22Sortino Ratio Rank
The Omega Ratio Rank of 2137.HK is 33Omega Ratio Rank
The Calmar Ratio Rank of 2137.HK is 77Calmar Ratio Rank
The Martin Ratio Rank of 2137.HK is 44Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Brii Biosciences Ltd (2137.HK) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


2137.HK
Sharpe ratio
The chart of Sharpe ratio for 2137.HK, currently valued at -1.12, compared to the broader market-2.00-1.000.001.002.003.00-1.12
Sortino ratio
The chart of Sortino ratio for 2137.HK, currently valued at -2.34, compared to the broader market-4.00-2.000.002.004.00-2.34
Omega ratio
The chart of Omega ratio for 2137.HK, currently valued at 0.72, compared to the broader market0.501.001.500.72
Calmar ratio
The chart of Calmar ratio for 2137.HK, currently valued at -0.79, compared to the broader market0.001.002.003.004.005.00-0.79
Martin ratio
The chart of Martin ratio for 2137.HK, currently valued at -1.63, compared to the broader market0.0010.0020.0030.00-1.63
^GSPC
Sharpe ratio
The chart of Sharpe ratio for ^GSPC, currently valued at 1.81, compared to the broader market-2.00-1.000.001.002.003.001.81
Sortino ratio
The chart of Sortino ratio for ^GSPC, currently valued at 2.64, compared to the broader market-4.00-2.000.002.004.002.64
Omega ratio
The chart of Omega ratio for ^GSPC, currently valued at 1.31, compared to the broader market0.501.001.501.32
Calmar ratio
The chart of Calmar ratio for ^GSPC, currently valued at 1.38, compared to the broader market0.001.002.003.004.005.001.38
Martin ratio
The chart of Martin ratio for ^GSPC, currently valued at 7.21, compared to the broader market0.0010.0020.0030.007.21

Sharpe Ratio

The current Brii Biosciences Ltd Sharpe ratio is -1.12. A negative Sharpe ratio means that the risk-free rate is higher than the portfolio's return. This value does not convey any meaningful information.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00NovemberDecember2024FebruaryMarchApril
-1.12
1.80
2137.HK (Brii Biosciences Ltd)
Benchmark (^GSPC)

Dividends

Dividend History


Brii Biosciences Ltd doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%NovemberDecember2024FebruaryMarchApril
-98.02%
-4.53%
2137.HK (Brii Biosciences Ltd)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Brii Biosciences Ltd. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Brii Biosciences Ltd was 98.27%, occurring on Apr 16, 2024. The portfolio has not yet recovered.

The current Brii Biosciences Ltd drawdown is 98.02%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-98.27%Sep 21, 2021630Apr 16, 2024
-18%Aug 10, 20219Aug 20, 202111Sep 6, 202120
-9.92%Jul 23, 20213Jul 27, 20213Jul 30, 20216
-9.37%Jul 14, 20213Jul 16, 20213Jul 21, 20216
-5.23%Sep 14, 20211Sep 14, 20211Sep 15, 20212

Volatility

Volatility Chart

The current Brii Biosciences Ltd volatility is 20.98%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%10.00%20.00%30.00%40.00%NovemberDecember2024FebruaryMarchApril
20.98%
3.34%
2137.HK (Brii Biosciences Ltd)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Brii Biosciences Ltd over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Income Statement


Income Statement
Balance Sheet
Cash Flow
Annual
Quarterly

TTM
Revenue

Total Revenue

0.00

Cost Of Revenue

0.00

Gross Profit

0.00
Operating Expenses

Selling, General & Admin Expenses

0.00

R&D Expenses

0.00

Total Operating Expenses

0.00
Income

Income Before Tax

0.00

Operating Income

0.00

EBIT

0.00

Earnings From Continuing Operations

0.00

Net Income

0.00

Income Tax Expense

0.00

Interest Expense

0.00

Other Non-Operating Income (Expenses)

0.00

Extraordinary Items

0.00

Discontinued Operations

0.00

Effect Of Accounting Charges

0.00

Non Recurring

0.00

Minority Interest

0.00

Other Items

0.00
Values in undefined except per share items